DOI:
10.1039/D3RA02716C
(Paper)
RSC Adv., 2023,
13, 15810-15825
New 1,3,4-thiadiazoles as potential anticancer agents: pro-apoptotic, cell cycle arrest, molecular modelling, and ADMET profile†
Received
24th April 2023
, Accepted 11th May 2023
First published on 25th May 2023
Abstract
A series of novel 1,3,4-thiadiazoles was synthesized via the reaction of N-(5-(2-cyanoacetamido)-1,3,4-thiadiazol-2-yl)benzamide (3) with different carbon electrophiles and evaluated as potential anticancer agents. The chemical structures of these derivatives were fully elucidated using various spectral and elemental analyses. Out of 24 new thiadiazoles, derivatives 4, 6b, 7a, 7d, and 19 have significant antiproliferative activity. However, derivatives 4, 7a, and 7d were toxic to the normal fibroblasts, and therefore were excluded from further investigations. Derivatives 6b and 19 with IC50 at less than 10 μM and with high selectivity were selected for further studies in breast cells (MCF-7). Derivative 19 arrested the breast cells at G2/M probably through inhibition of CDK1, while 6b significantly increased the sub-G1 percent of cells probably through induction of necrosis. These results were confirmed by the annexin V-PI assay where 6b did not induce apoptosis and increased the necrotic cells to 12.5%, and compound 19 significantly increased the early apoptosis to 15% and increased the necrotic cells to 15%. Molecular docking showed that compound 19 was like FB8, an inhibitor of CDK1, in binding the CDK1 pocket. Therefore, compound 19 could be a potential CDK1 inhibitor. Derivatives 6b and 19 did not violate Lipinski's rule of five. In silico studies showed that these derivatives have a low blood–brain barrier penetration capability and high intestinal absorption. Taken together, derivatives 6b and 19 could serve as potential anticancer agents and merit further investigations.
1. Introduction
Heterocyclic compounds are key structural moieties in several anticancer drugs. According to the FDA, most novel molecular anticancer agents contain heterocyclic rings within their structures.1 Due to their adaptability, heterocycle-based drugs can easily target various metabolic pathways and cellular processes in cancer pathology.2 Various heterocyclic compounds have been synthesized and reported for their potential applications as therapeutic agents. Among these compounds, the five-membered heterocyclic scaffolds, oxadiazoles, triazoles, and thiadiazoles are the most significant compounds. Thiadiazoles have been reported to exhibit several biological activities. Among the thiadiazole isomers, 1,3,4-derivatives showed preferable metabolic stability and availability.3 This is the most promising moiety with different therapeutic activities such as anticancer,4 antiviral,5 anti-inflammatory,6 antidiabetic activity,7 and antidepressant activity.8
The interesting pharmacological properties of 1,3,4-thiadiazoles is attributed to their high aromaticity, in vivo stability, and lack of toxicity.9 Moreover, the capability of the hydrogen binding domain allows the use of 1,3,4-thiadiazole as one of the potential agents in many FDA-approved10 drugs such as desaglybuzole, acetazolamide, sulfamethizole, litronesib, filanesib, and methazolamide11 (Fig. 1).
![image file: d3ra02716c-f1.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-f1.gif) |
| Fig. 1 FDA-approved drugs of 1,3,4-thiadiazole derivatives showing their common pharmacophoric features. | |
The present study aimed at synthesizing new thiadiazole derivatives and investigating the antiproliferative effect on various human cell lines as well as investigating the possible mechanism(s) of action through assessing the effect of these derivatives on cell cycle and apoptosis by flow cytometry. Different in silico and docking studies were performed to predict some of the pharmacological characteristics of the new thiadiazoles.
2. Experimental
2.1 Chemistry
All melting points were determined using uncorrected Griffin and George melting-point equipment (Griffin & George Ltd., Wembley, Middlesex, UK). The quality of the produced compounds was controlled using aluminum sheet silica gel F254 (Merck) thin layer chromatography (TLC). The KBr wafer approach was used to record IR-spectra using a Pye Unicam SP1200 spectrophotometer (Pye Unicam Ltd., Cambridge, UK). 1H-NMR spectra were obtained on a Bruker Avance (III) utilizing a Varian-Gemini 400 MHz and an internal standard of tetramethyl silane (chemical shifts in scale δppm), whereas 13C-NMR spectra were obtained at 100 MHz. In deuterated dimethyl sulfoxide, TMS was used as an internal standard (DMSO-d6). Chemical changes were described as elemental studies were performed using a PerkinElmer 2400 CHN elemental analyzer at the Microanalytical Unit, Faculty of Science, Ain Shams University, and satisfactory analytical data (±0.4) were obtained for all derivatives.
2.1.1 N-(5-Amino-1,3,4-thiadiazol-2-yl)benzamide (2). Method (I): a solution of N-(2-carbamothioylhydrazine-1-carbonothioyl)benzamide (1) (2.5 g, 10 mmol) in acetic acid (15 mL) was refluxed for three hours. The deposited solid while heating was filtered off and then recrystallized from acetic acid affording the pure compound 2 as yellow crystals; (2.1 g, 91%); m.p. 278–280 °C; IR (KBr) (υmax, cm−1): 3448, 3446 (NH2), 3164 (NH), 3060 (CH aromatic), 1672, 1638 (C
O), 1601 (C
N). Anal. calcd for C9H8N4OS (220.25) C, 49.08; H, 3.66; N, 25.44; found: C, 49.18; H, 3.63; N, 25.60.Method (II): a mixture of N-(2-carbamothioylhydrazine-1-carbonothioyl)benzamide (1) (2.5 g, 10 mmol) and sulfuric acid 98% (10 mL) was stirred at room temperature for 1.5 h, kept in refrigerator overnight, and then poured onto cold water. The precipitated solid was separated by filtration, dried, and recrystallized from N,N-dimethyl formamide affording the pure compound 2 as yellow crystals; (1.1 g, 50%) (identity m.p., TLC, and IR).
2.1.2 N-(5-(2-Cyanoacetamido)-1,3,4-thiadiazol-2-yl)benzamide (3). A mixture of compound 2 (2.2 g, 10 mmol) and ethyl cyanoacetate (1.13 mL, 10 mmol) with a catalytic amount of TEA was stirred in 10 mL of absolute ethanol for three hours. The reaction mixture was acidified by cold dilute HCl, the deposited solid was filtered off and recrystallized from EtOH/dioxane [1
:
3] giving the pure compound 3 as yellow crystals; (2.1 g, 75%); m.p. 204–206 °C; IR (KBr) (υmax, cm−1): 3213 (NH), 3080 (CH aromatic), 2918, 2894 (CH aliphatic), 2257 (C
N), 1691, 1673 (C
O), 1612 (C
N). 1H-NMR (300 MHz, DMSO-d6) δppm: 3.88 (s, 2H, CH2), 7.46–7.95 (m, 5H, ArH), 11.69 (br s, 1H,
, exchangeable with D2O), 12.59 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 24.06, 115.46, 115.60, 128.53, 128.84, 131.83, 133.30, 160.11, 166.58, 167.40, 168.10, 178.14. Anal. calcd for C12H9N5O2S (287.30) C, 50.17; H, 3.16; N, 24.38; found: C, 50.27; H, 3.01; N, 24.30.
2.1.3 N-(5-Benzamido-1,3,4-thiadiazol-2-yl)-2-imino-2H-chromene-3-carboxamide (4). A mixture of compound 3 (2.8 g, 10 mmol) and salicylaldehyde (1.2 mL, 10 mmol) with a catalytic amount of piperidine in absolute ethanol 10 mL was heated under reflux for three hours. The deposited solid while heating was collected by filtration, dried, and recrystallized from dioxane producing 4 as orange crystals; (3.5 g, 84%); m.p. 240–242 °C; IR (KBr) (υmax, cm−1): 3409, 3158 (NH), 3060, 3044 (CH aromatic), 2971 (CH aliphatic), 1679 (C
O), 1636 (C
N). 1H-NMR (300 MHz, DMSO-d6) δppm: 7.28–8.00 (m, 9H, ArH), 8.58 (s, 1H, C
CH olefinic), 11.76 (br s, 1H,
, exchangeable with D2O), 13.98 (br s, 2H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 115.41, 118.12, 118.50, 124.71, 128.58 (2C), 128.70, 128.86, 129.40, 130.40, 131.94, 133.01, 133.27, 133.78, 142.42, 153.24, 156.25, 156.80, 168.39. Anal. calcd for C19H13N5O3S (391.41) %: C, 58.31; H, 3.35; N, 17.89; found: C, 58.28; H, 3.38; N, 17.70.The filtrate was acidified by cold dilute HCl. The deposited solid was filtered out, dried, and recrystallized from EtOH/dioxane [3
:
1] affording compound 5.
2.1.4 N-(5-Benzamido-1,3,4-thiadiazol-2-yl)-2-oxo-2H-chromene-3-carboxamide (5). Yellow crystals; (3 g, 78%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3221, 3179 (NH), 3038 (CH aromatic), 1713 (C
Olactone), 1679, 1655 (C
Oamide), 1608 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.48–7.57 (m, 5H, ArH), 7.66 (d, J = 7.24 Hz, 1H, ArH), 7.79 (d, J = 7.76 Hz, 1H, ArH), 8.00–8.08 (m, 2H, ArH), 9.04 (s, 1H, C
CH olefinic), 12.20 (br s, 1H, NH, exchangeable with D2O), 13.74 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 104.51, 116.56, 117.96, 120.23, 123.32, 123.76, 126.28 (2C), 128.58, 130, 131.67, 134.63, 140.30 (2C), 152.43 (2C), 166.99 (2C), 169.65. Anal. calcd for C19H12N4O4S (392.39) %: C, 58.16; H, 3.08; N, 14.28; found: C, 58.20; H, 3.10; N, 14.25.
2.1.5 N-(5-(6-amino-4-argio-3,5-dicyano-2-oxopyridin-1(2H)-yl)-1,3,4-thiadiazol-2-yl)benzamide (6a). A mixture of compound 3 (2.8 g, 10 mmol) and 2-(4-methoxy-benzylidene)malononitrile “arylidene” (1.8 g, 10 mmol) with a catalytic amount of piperidine was refluxed in absolute ethanol 10 mL for 4.5 h. The precipitated crystals were filtered off and washed with boiling ethanol affording compound 6a as gray crystals; (3.3 g, 73%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3455, 3394 (NH2), 3263 (NH), 3099 (CH aromatic), 2944, 2844 (CH aliphatic), 2219 (C
N), 1660, 1641 (C
O). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.88 (s, 3H, OCH3), 5.59 (s, 2H, NH2, exchangeable with D2O), 7.18 (d, J = 8.80 Hz, 2H, ArH), 7.54 (t, J = 7.76 Hz, 2H, ArH), 7.67 (t, J = 7.4 Hz, 1H, ArH), 7.97–8.22 (m, 4H, ArH), 12.42 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 66.13, 71.23, 116.39, 117.57, 121.90, 123.72, 124.02, 124.39, 126.28, 127.08 (2C), 127.74, 129.80, 130.83, 132.22, 135.78, 147.67, 152.57, 153.56, 153.81, 162.56, 170.13, 170.20. Anal. calcd for C23H15N7O3S (469.48) %: C, 58.84; H, 3.22; N, 20.88; found: C, 58.80; H, 3.28; N, 20.82.The reaction filtrate was poured onto ice cold dilute HCl with stirring. The crude material was filtered off and recrystallized from dioxane giving 6b.
2.1.6 N-(5-(2-Cyano-3-(4-methoxyphenyl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (6b). Orange crystals; (2.6 g, 65%); m.p. 252–254 °C; IR (KBr) (υmax, cm−1): 3233 (NH), 3066, 3020 (CH aromatic), 2984, 2935 (CH aliphatic), 2207 (C
N), 1681 (C
O). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.88 (s, 3H, OCH3), 7.18 (d, J = 8.80 Hz, 2H, ArH), 7.54 (t, J = 7.76 Hz, 2H, ArH), 7.67 (t, J = 7.4 Hz, 1H, ArH), 7.97–8.04 (m, 4H, ArH), 8.22 (s, 1H,
CH olefinic), 11.11 (br s, 1H, NH, exchangeable with D2O), 11.81 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 20.58, 55.62, 112.29 (2C), 114.63 (2C), 118.80, 127.50 (2C), 128.99 (2C), 129.53 (2C), 137.06 (2C), 146.06 (2C), 159.78, 170.44, 178.66. Anal. calcd for C20H15N5O3S (405.43) %: C, 59.25; H, 3.73; N, 17.27; found: C, 59.30; H, 3.70; N, 17.30.
2.1.7 General procedure for the synthesis of compounds (7a–f). A mixture of compound 3 (2.8 g, 10 mmol) and the appropriate aldehyde derivatives namely; 2,4-dichlorobenzaldehyde (1.7 g, 10 mmol), p-chlorobenzaldehyde (1.4 g, 10 mmol), furan-2-carbaldehyde (0.96 mL, 10 mmol), thiophene-2-carbaldehyde (1.2 mL, 10 mmol), p-nitrobenzaldehyde (1.5 g, 10 mmol), or 4-hydroxy-3-methoxybenzaldehyde (1.5 g, 10 mmol) in absolute ethanol (10 mL) in the presence of a catalytic amount of piperidine was refluxed for three hours. The precipitated crystals were filtered off and recrystallized from ethanol affording compounds 7a–f.
2.1.8 N-(5-(2-Cyano-3-(2,4-dichlorophenyl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7a). Yellow crystals; (3.1 g, 72%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3197, 3154 (NH), 3095, 3069, 3019 (CH aromatic), 2921 (CH aliphatic), 2229 (C
N), 1660 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.57–8.17 (m, 8H, ArH), 8.29 (s, 1H,
CHolefinic), 12.72 (br s, 1H, NH, exchangeable with D2O), 13.47 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 103.93, 112.94, 115.85, 117.93, 129.74 (2C), 131.93 (2C), 132.04, 136.85 (2C), 146.12, 146.39, 148.22, 156.91, 159.10, 160.49, 170.08, 170.69. Anal. calcd for C19H11Cl2N5O2S (444.29) %: C, 51.36; H, 2.50; Cl, 15.96; N, 15.76; found: C, 51.30; H, 2.43; Cl, 15.89; N, 15.80.
2.1.9 N-(5-(3-(4-Chlorophenyl)-2-cyanoacrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7b). Orange crystals; (3.2 g, 80%); m.p. 258–260 °C; IR (KBr) (υmax, cm−1): 3237 (NHbr), 3056 (CH aromatic), 2970 (CH aliphatic), 2212 (C
N), 1686, 1665 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.53–8.02 (m, 9H, ArH), 8.29 (s, 1H,
CHolefinic), 11.28 (br s, 1H,
, exchangeable with D2O), 12.40 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 68.28, 70.01, 120.90, 123.02, 123.13, 125.59, 126.03, 126.71, 127, 128.11, 128.46, 128.55, 129.80, 129.89, 135.19, 146.74, 167.69, 170.62, 170.77. Anal. calcd for C19H12ClN5O2S (409.85) %: C, 55.68; H, 2.95; Cl, 8.65; N, 17.09; found: C, 55.70; H, 2.98; Cl, 8.72; N, 17.15.
2.1.10 N-(5-(2-Cyano-3-(furan-2-yl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7c). White crystals; (3.4 g, 95%); m.p. 276–278 °C; IR (KBr) (υmax, cm−1): 3291, 3238 (NH), 3067, 3040 (CH aromatic), 2215 (C
N), 1684, 1664 (C
Oamide), 1614 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 6.87–6.88 (m, 1H, ArH), 7.48–7.56 (m, 4H, ArH), 7.67 (t, J = 7.36 Hz, 2H, ArH), 7.97–8.08 (m, 1H, ArH), 8.20 (s, 1H,
CHolefinic), 11.82 (br s, 1H,
, exchangeable with D2O), 12.43 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 102.91, 117.04, 118.04, 121.51, 124.32, 124.76, 127.11 (2C), 129.58 (2C), 131.00, 132.67, 135.63, 141.39, 153.43, 167.98, 170.65. Anal. calcd for C17H11N5O3S (365.37) %: C, 55.89; H, 3.03; N, 19.17; found: C, 55.93; H, 3.10; N, 19.15.
2.1.11 N-(5-(2-Cyano-3-(thiophen-2-yl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7d). Gray crystals; (3.2 g, 85%); m.p. 268–270 °C; IR (KBr) (υmax, cm−1): 3244 (NH), 3098, 3018 (CH aromatic), 2924 (CH aliphatic), 2209 (C
N), 1687, 1667 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.36 (t, J = 8.76 Hz, 1H, ArH), 7.54 (t, J = 7.84 Hz, 2H, ArH), 7.67 (t, J = 7.4 Hz, 1H, ArH), 7.97–7.99 (m, 3H, ArH), 8.18 (d, J = 4.96 Hz, 1H, ArH), 8.52 (s, 1H,
CHolefinic), 11.82 (br s, 1H,
, exchangeable with D2O), 12.41 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 109.22, 119.18 (2C), 120.67, 123.35, 126.23, 126.67, 129.11, 131.85, 133.27, 134.76, 137.48, 143.22, 155.37 (2C), 169.99, 172.42. Anal. calcd for C17H11N5O2S2 (381.43) %: C, 53.53; H, 2.91; N, 18.36; found: C, 53.58; H, 2.80; N, 18.25.
2.1.12 N-(5-(2-Cyano-3-(4-nitrophenyl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7e). Yellow crystals; (3.0 g, 73%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3203, 3154 (NH), 3068, 3053 (CH aromatic), 2936 (CH aliphatic), 2233 (C
N), 1669 (C
O). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.59 (t, J = 7.32 Hz, 2H, ArH), 7.69 (t, J = 7.2 Hz, 1H, ArH), 8.15 (d, J = 7.48 Hz, 2H, ArH), 8.25 (d, J = 8.16 Hz, 2H, ArH), 8.40–8.45 (m, 2H, ArH + 1H,
CHolefinic), 12.55 (br s, 1H, NH, exchangeable with D2O), 13.45 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 112.94, 113.29, 116.98, 117.83, 129.28, 129.52, 130.28 (2C), 131.05, 131.25, 134.62, 135.78, 148.16, 154.35, 160.65, 161.47, 170.82, 174.14, 174.73. Anal. calcd for C19H12N6O4S (420.40) %: C, 54.28; H, 2.88; N, 19.99; found: C, 54.30; H, 2.85; N, 19.90.
2.1.13 N-(5-(2-Cyano-3-(4-hydroxy-3-methoxyphenyl)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (7f). Pale yellow crystals; (3.7 g, 90%); m.p. 240–242 °C; IR (KBr) (υmax, cm−1): 3259 (OH), 3181, 3106 (NH), 3006 (CH aromatic), 2922, 2839 (CH aliphatic), 2219 (C
N), 1667 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.85 (s, 3H, OCH3), 6.96 (d, J = 8.32 Hz, 1H, ArH), 7.56–7.78 (m, 5H, ArH), 8.11–8.15 (m, 2H, ArH + 1H,
CHolefinic), 10.24 (br s, 1H, OH, exchangeable with D2O), 12.07 (br s, 1H, NH, exchangeable with D2O), 13.30 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 65.73, 66.81, 68.92, 116.04, 117.41, 120.44, 123.33, 123.69, 126.08, 128.56, 129.98, 131.66, 134.43, 140.38, 152.45, 158.87, 159.51, 166.93, 168.85, 169.66. Anal. calcd for C20H15N5O4S (421.43) %: C, 57.00; H, 3.59; N, 16.62; found: C, 57.09; H, 3.62; N, 16.58.
2.1.14 General procedure for the synthesis of compounds (9 and 10). A mixture of compound 3 (2.8 g, 10 mmol) and the appropriate diketone derivatives namely acetylacetone (1.00 mL, 10 mmol) or benzoyl acetone (1.6 mL, 10 mmol) in absolute ethanol (10 mL) with a catalytic base of fused sodium acetate was refluxed for three hours. The separated solid was filtered off, dried, and recrystallized from ethanol affording compounds 9 and 10, respectively.
2.1.15 N-(5-(3-Cyano-4,6-dimethyl-2-oxopyridin-1(2H)-yl)-1,3,4-thiadiazol-2-yl)benzamide (9). White crystals; (2.2 g, 64%); m.p. 298–300 °C; IR (KBr) (υmax, cm−1): 3224 (NH), 3054, 3021 (CH aromatic), 2964, 2922 (CH aliphatic), 2215 (C
N), 1648 (C
O). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.96 (s, 3H, CH3), 3.99 (s, 3H, CH3), 7.54–8.11 (m, 6H, ArH), 12.87 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 21.01, 21.13, 115.85, 116.66, 120.90, 123.13, 125.59, 126.71, 127.77, 129.80, 135.19, 152.70, 161.70, 167.67, 170.77, 180.28, 182.01. Anal. calcd for C17H13N5O2S (351.38) %: C, 58.11; H, 3.73; N, 19.93; found: C, 58.20; H, 3.65; N, 19.88.
2.1.16 N-(5-(3-Cyano-4-methyl-2-oxo-6-phenylpyridin-1(2H)-yl)-1,3,4-thiadiazol-2-yl)benzamide (10). White crystals; (2.4 g, 60%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3258, 3174 (NH), 3067 (CH aromatic), 2970, 2934 (CH aliphatic), 2218 (C
N), 1684 (C
O), 1649 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 2.15 (s, 3H, CH3), 7.57–8.30 (m, 11H, ArH), 13.37 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 22.83, 68.92, 116.04 (2C), 117.41, 120.44, 123.33, 123.69, 126.08 (2C), 128.56, 129.98, 131.66, 134.43, 140.38, 152.45, 158.87, 159.51, 166.93, 168.85 (2C), 169.66. Anal. calcd for C22H15N5O2S (413.46) %: C, 63.91; H, 3.66; N, 16.94; found: C, 63.88; H, 3.71; N, 16.81.
2.1.17 General procedure for the synthesis of compounds (11–16). 1,3,4-Thiadiazole derivative 3 (2.8 g, 10 mmol) was added to a cold suspension of finely divided potassium hydroxide (0.56 g, 10 mmol) in DMF (15 mL) with stirring for 30 minutes. Phenyl isothiocyanate (1.35 mL, 10 mmol) was added dropwise and then the mixture was allowed to stand overnight. Ethyl chloroacetate (1.22 mL, 10 mmol), chloro acetylchloride (1.12 mL, 10 mmol), diethyl malonate (1.6 mL, 10 mmol), 1,2-dibromoethane (1.87 mL, 10 mmol), methyl iodide (1.41 mL, 10 mmol), or HCl was added dropwise, stirred at room temperature for three hours and then allowed to stand overnight. The reaction mixture was placed into ice cold dilute HCl. The separated solid was filtered, washed with water, dried, and recrystallized from the suitable solvent producing 11–16, respectively.
2.1.18 Ethyl (E,Z)-2-((3-((5-benzamido-1,3,4-thiadiazol-2-yl)amino)-2-cyano-3-oxo-1-(phenylamino) prop-1-en-1-yl)thio)acetate (11). Brown crystals; (2.7 g, 55%); m.p. 288–290 °C; IR (KBr) (υmax, cm−1): 3148 (NH), 3064 (CH aromatic), 2982 (CH aliphatic), 2195 (C
N), 1734 (C
Oester), br. 1673 (C
Oamide), 1637 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 1.19 (t, 3H,
), 4.06 (q, 2H,
), 4.59 (s, 2H,
), 6.75–6.77 (m, 5H, ArH), 7.66–8.07 (m, 5H, ArH), 11.96 (br s, 1H,
, exchangeable with D2O), 12.85–13.05 (br s, 2H,
, exchangeable with D2O). Anal. calcd for C23H20N6O4S2 (508.57) %: C, 54.32; H, 3.96; N, 16.53; found: C, 54.25; H, 3.87; N, 16.59.
2.1.19 N-(5-(2-Cyano-2-(5-oxo-3-phenylthiazolidin-2-ylidene)acetamido)-1,3,4-thiadiazol-2-yl)benzamide (12). Red crystals; (3.0 g, 64%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3210, 3154 (NH), 3061 (CH aromatic), 2922 (CH aliphatic), 2204 (C
N), 1741 (C
OKetone), br. 1670 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 4.10 (s, 2H,
), 6.72–6.77 (m, 5H, ArH), 7.64–8.05 (m, 5H, ArH), 12.95 (br s, 1H, NH, exchangeable with D2O), 14.69 (br s, H, NH, exchangeable with D2O). Anal. calcd for C21H14N6O3S2 (462.50) %: C, 54.54; H, 3.05; N, 18.17; found: C, 54.51; H, 3.13; N, 18.11.
2.1.20 N-(5-(2-Cyano-2-(4,6-dioxo-1-phenylpiperidin-2-ylidene)acetamido)-1,3,4-thiadiazol-2-yl)benzamide (13). Reddish brown crystals; (2.7 g, 58%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3150 (NH), 3064 (CH aromatic), 2981 (CH aliphatic), 2206 (C
N), 1740 (C
OKetone), 1672 (C
Oamide), 1638 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 4.62 (s, 2H,
), 7.49–7.59 (m, 5H, ArH), 7.84–8.04 (m, 5H, ArH), 11.89 (br s, 1H, NH, exchangeable with D2O), 12.50 (br s, 1H, NH, exchangeable with D2O). Anal. calcd for C22H14N6O4S2 (490.51) %: C, 53.87; H, 2.88; N, 17.13; found: C, 53.96; H, 2.94; N, 17.09.
2.1.21 N-(5-(2-Cyano-2-(3-phenylthiazolidin-2-ylidene)acetamido)-1,3,4-thiadiazol-2-yl)benzamide (14). Reddish brown crystals; (2.9 g, 68%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3157 (NH), 3055 (CH aromatic), 2962, 2921 (CH aliphatic), 2174 (C
N), 1673 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.75–3.85 (m, 4H,
), 6.72–6.77 (m, 5H, ArH), 7.55–8.05 (m, 5H, ArH), 9.21 (br s, 1H, NH, exchangeable with D2O), 13.01 (br s, 1H, NH, exchangeable with D2O). Anal. calcd for C21H16N6O2S2 (448.52) %: C, 56.24; H, 3.60; N, 18.74; found: C, 56.29; H, 3.55; N, 18.64.
2.1.22 N-(6-Cyano-7-oxo-5-(phenylamino)-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)benzamide (15). Brown crystals; (2.7 g, 73%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3418 (NH), 3060 (CH aromatic), 2923 (CH aliphatic), 2192 (C
N), 1688 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.05–7.59 (m, 10H, ArH), 12.47 (br s, 1H,
, exchangeable with D2O), 13.74 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 68, 116, 117, 120, 123.32, 123.76, 126, 128, 130, 131, 134, 140, 152, 166, 169, 180. Anal. calcd for C19H12N6O2S (388.41) %: C, 58.76; H, 3.11; N, 21.64; found: C, 58.65; H, 3.14; N, 21.59.
2.1.23 N-(5-(2-Cyano-3-(phenylamino)-3-thioxopropanamido)-1,3,4-thiadiazol-2-yl)benzamide (16). Brown crystals; (2.2 g, 54%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): 3283, 3211 (NH), 3063 (CH aromatic), 2923 (CH aliphatic), 2205 (C
N), 1669 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 3.5 (s, 1H,
), 7.46–7.67 (m, 5H, ArH), 8.12–8.13 (m, 5H, ArH), 9.24 (br s, 1H, NH, exchangeable with D2O), 13.10 (br s, 1H, NH, exchangeable with D2O), 13.15 (br s, 1H,
, exchangeable with D2O). Anal. calcd for C19H14N6O2S2 (422.48) %: C, 54.02; H, 3.34; N, 19.89; found: C, 54.05; H, 3.36; N, 19.85.
2.1.24 N-(5-(2-Cyano-3,3-bis(methylthio)acrylamido)-1,3,4-thiadiazol-2-yl)benzamide (17). 1,3,4-Thiadiazole derivative 3 (2.8 g, 10 mmol) was added to a cold suspension of finely divided potassium hydroxide (0.56 g, 10 mmol) in DMF (15 mL) with stirring for 30 minutes. Carbon disulfide (2 mL) was added dropwise and then, the mixture was allowed to stand overnight. Methyl iodide (1.4 mL, 10 mmol) was added dropwise, stirred at room temperature for three hours and then, allowed to stand overnight. With stirring, the reaction mixture was placed into ice-cold dilute HCl. The separated solid was filtered, washed with water, dried, and crystallized from dioxane producing 17 as yellow crystals; (2.3 g, 60%); m.p. 250–252 °C; IR (KBr) (υmax, cm−1): 3160 (NH), 3002 (CH aromatic), 2932 (CH aliphatic), 2213 (C
N), 1664 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 2.67 (s, 3H,
), 2.70 (s, 3H,
), 7.51–8.26 (m, 5H, ArH), 13.25 (br s, 1H,
, exchangeable with D2O), 14.74 (br s, 1H,
, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 20.98 (2C), 69.90, 117.06, 118.04, 121.52, 127.10, 129.60, 131.00, 132.68, 133.65, 141.38, 153.43, 167.99, 170.64. Anal. calcd for C15H13N5O2S3 (391.48) %: C, 46.02; H, 3.35; N, 17.89; found: C, 46.15; H, 3.42; N, 17.93.
2.1.25 General procedure for the synthesis of compounds (18–20). A mixture of compound 17 (1.9 g, 5 mmol) and the appropriate bidentate derivatives namely, o-phenylenediamine (0.9 g, 5 mmol), o-aminophenol (0.5 g, 5 mmol), or 2,3-dihydroxypyridine (0.5 g, 5 mmol) in dioxane (10 mL) with a catalytic amount of triethylamine was refluxed for four hours. The precipitated solid was filtered off, dried, and crystallized from ethanol/dioxane [1
:
3] affording compounds 18–20, respectively.
2.1.26 N-(5-(2-Cyano-2-(1,3-dihydro-2H-benzo[d]imidazole-2-ylidene)acetamido)-1,3,4-thiadiazol-2-yl)benzamide (18). Pale yellow crystals; (2.7 g, 68%); m.p. > 300 °C; IR (KBr) (υmax, cm−1): br. 3191 (NH), 3054 (CH aromatic), 2979 (CH aliphatic), 2171 (C
N), br. 1688 (C
Oamide). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.18–7.20 (m, 2H, ArH), 7.36–7.68 (m, 5H, ArH), 8.12 (d, J = 7.52 Hz, 2H, ArH), 11.24 (br s, 1H,
, exchangeable with D2O), 12.5 (br s, 2H,
, exchangeable with D2O), 14.52 (br s, 1H,
, exchangeable with D2O). Anal. calcd for C19H13N7O2S (403.42) %: C, 56.57; H, 3.25; N, 24.30; found: C, 56.47; H, 3.32; N, 24.41.
2.1.27 N-(5-(2-(Benzo[d]oxazol-2(3H)-ylidene)-2-cyanoacetamido)-1,3,4-thiadiazol-2-yl)benzamide (19). Pale yellow crystals; (3.4 g, 81%); m.p. 200–202 °C; IR (KBr) (υmax, cm−1): 3187, 3134 (NH), 3063 (CH aromatic), 2209 (C
N), br. 1665 (C
Oamide), 1634 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 6.73 (t, J = 7.24 Hz 1H, ArH), 6.96 (d, J = 8.72 Hz, 2H, ArH), 7.07 (d, J = 7.72 Hz, 1H, ArH), 7.21 (t, J = 8.24 Hz, 4H, ArH), 7.60 (d, J = 8.72 Hz, 1H, ArH), 10.15 (br s, 1H,
, exchangeable with D2O), 12.87 (br s, 1H, NH, exchangeable with D2O), 14.14 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 55.62, 112.29 (2C), 114.63 (2C), 118.80, 127.50, 128.99 (2C), 129.53 (2C), 137.06 (2C), 146.06, 154.68, 155.99 (2C), 159.78, 185.65. Anal. calcd for C19H12N6O3S (404.40) %: C, 56.43; H, 2.99; N, 20.78; found: C, 56.39; H, 2.85; N, 20.81.
2.1.28 N-(5-(2-([1,3]dioxolo[4,5-b]pyridin-2-ylidene)-2-cyanoacetamido)-1,3,4-thiadiazol-2-yl)benzamide (20). Brown crystals; (2.1 g, 54%); m.p. 226–228 °C; IR (KBr) (υmax, cm−1): 3190, 3147 (NH), 3064 (CH aromatic), 2993 (CH aliphatic), 2209 (C
N), br. 1665 (C
Oamide), 1633 (C
N). 1H-NMR (400 MHz, DMSO-d6) δppm: 7.21 (d, J = 9.12 Hz, 1H, ArH), 7.36–7.39 (m, 2H, ArH), 7.59–7.63 (m, 2H, ArH), 8.01 (t, J = 6.8 Hz, 1H, ArH), 8.63 (d, J = 8.3 Hz, 2H, ArH), 11.9 (br s, 1H, NH, exchangeable with D2O), 12.34 (br s, 1H, NH, exchangeable with D2O). 13C-NMR (100 MHz, DMSO-d6) δppm: 66.81, 116.04, 117.41, 120.44, 123.33, 123.69, 126.08, 128.56, 129.98, 131.66, 134.43, 158.87, 159.51, 166.93, 168.85, 169.66, 185.16, 192.83. Anal. calcd for C18H10N6O4S (406.38) %: C, 53.20; H, 2.48; N, 20.68; found: C, 53.18H, 2.55; N, 20.74.
2.2. Biological evaluation
2.2.1 Antiproliferative activity. All cell lines and media were obtained from the ATCC (Virginia, USA). The cells were cultured using the media and conditions recommended by the ATCC. The cell viability was determined using MTT as described elsewhere.12–14 Briefly, the cells were seeded at a density of 2 × 106 per well in 48-well plate. The cells were treated with the thiadiazole derivatives (0.5–100 μM) and incubated for 48 h. For comparison, untreated control cells and cells treated with doxorubicin were run under the same conditions. The data were expressed as mean ±SEM for three independent experiments. The study was approved by the Research Ethics Committee at Ain shams University and was performed in accordance with the guidelines of the National Institute of Health (NIH).
2.2.2 Cell cycle analysis. MCF-7 cells were seeded in 6-well plate (2 mL per well) overnight at 37 °C and 5% CO2. The cells were incubated with serum-free medium for 24 hours, then cells were treated with the IC50 concentration of 6b or 19 for 48 h. After incubation, cells were washed twice with ice-cold 1× PBS and collected after trypsinization. The cells were centrifuged at 500×g for five minutes at 4 °C. The cell pellet was resuspended in ice-cold 1× PBS and fixed with absolute ethanol and incubated at −20 °C for two hours. The fixed cells were then washed with ice-cold 1× PBS. Cell pellet was resuspended in propidium (PI)/RNase (BD Biosciences, BDB550825, NJ, USA) and incubated for 30 min at room temperature in dark, then DNA content in each phase was measured using BD FACSCanto II™ Flow Cytometer. More details could be reviewed elsewhere.15
2.2.3 Apoptosis assay by annexin V. MCF-7 cells were seeded in a 6-well plate (1 × 105 cells per mL) and incubated overnight at 37 °C and 5% CO2. To a fresh medium, DMSO, 6b, or 19 was added at the IC50 concentration and incubated for 48 hours. The cells were trypsinized, harvested, and washed twice with 1× PBS. The cells were stained with 5 μL annexin-V/FITC and 5 μL propidium iodide (Elabscience Biotechnology Inc, E-CK-A211) in the binding buffer for 15 minutes. The stained cells were analyzed by BD FACSCanto II™ flow cytometer.
2.2.4 Statistical analysis of data. The data distribution was examined by the Kolmogorov–Smirnov test. Results were expressed as mean ±SEM. The statistical analyses were performed using one-way analysis of variance followed by the Tukey-HSD test for multiple comparisons. Differences were considered significant at p < 0.05.
2.3. In silico studies
2.3.1 Docking studies. Using the MOE 2019 suite, the newly designed and synthesized compounds (6b and 19) were proposed as CDK1.16 As a result, two separate docking processes were performed for the investigated derivatives towards CDK1, with the co-crystallized inhibitor (FB8) serving as a reference standard.
2.3.2 Preparation of the newly designed and synthesized derivatives. As previously mentioned,17 all of the synthesized derivatives were prepared for docking by adding partial charges and minimizing energy after being sketched using the ChemDraw professional program and added to the MOE program window. With the extracted co-crystallized FB8 in the case of CDK1 docking process.
2.3.3 CDK-1 pockets preparation and docking. The protein data bank was used to obtain the X-ray structures of the CDK-1 proteins (PDB codes ID: 6GU7). In each case, the target proteins were 3D protonated, error corrected, and energy minimized before being docked, as previously described in detail.18 According to each instance's default methodology, the two docking processes were carried out in accordance with the general docking protocol. For additional research, the docked poses with the most acceptable binding scores, RMSD values, and binding modes16 were chosen.
2.3.4 Pharmacokinetic profiling. Discovery studio 2.5 was used to investigate the pharmacokinetic profile of the tested derivatives and FB8 as previously described.
2.3.5 ADMET predictions. Using Discovery Studio 2.5, the tested candidates' ADMET descriptors-namely, absorption, distribution, metabolism, excretion, and toxicity-were assessed. According to the default protocol, the target derivatives and FB8 were prepared and minimized.19 After that, ADMET studies were conducted.20
3. Results and discussion
3.1 Chemistry
As a part of our ongoing research that aims at developing simple and efficient synthetic techniques for the synthesis of novel heterocyclic compounds with potential anticancer applications,21–31 the present study reported the synthesis of numerous new substituted 1,3,4-thiadiazole derivatives incorporating benzene moiety. N-(5-Amino-1,3,4-thiadiazol-2-yl)benzamide (2) was synthesized as a sole product through reaction of benzoylisothiocyanate with thiosemicarbzide in dry acetonitrile and then underwent cyclization according to the previously published methodology32–36 (Scheme 1). Treatment of compound 2 with ethyl cyanoacetate in the presence of a catalytic amount of triethylamine afforded N-(5-(2-cyanoacetamido)-1,3,4-thiadiazol-2-yl)benzamide (3) in a high yield, which was used as a key starting material (Scheme 1). The structures of compounds 2 and 3 were deduced from their elemental and spectral analyses.
![image file: d3ra02716c-s1.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-s1.gif) |
| Scheme 1 Synthesis of 1,3,4-thiadiazole derivative 3. | |
The nucleophilic reactivity of the intermediate 3 towards various carbon electrophiles has been investigated. Refluxing compound 3 with salicylaldehyde in an ethanolic solution containing a catalytic amount of piperidine yielded 2-iminocoumarin derivative 4 (Scheme 2). The presence of absorption bands for –NH groups at 3409 and 3158 cm−1 along with the absence of absorption band for the nitrile group confirmed the assigned structure 4. In addition, acidification of the filtrate gave the expected coumarin derivative 5 (Scheme 2). Ample evidence for the assigned structure 5 was forthcoming from the correct elemental analysis and spectral data. The presence of a high frequency C
O stretching at 1713 cm−1 was attributed to the coumarin oxo-group in the IR spectrum as well as the absence of NH proton of imino group at 11.76 ppm in the 1H-NMR spectrum of compound 5 agrees well with the proposed structure.
![image file: d3ra02716c-s2.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-s2.gif) |
| Scheme 2 Reaction of the β-ketonitrile 3 with some aromatic aldehydes and arylidene derivatives. | |
Subjecting compound 3 to react with 2-(4-methoxybenzylidene)malononitrile gave a grey crystalline product upon reflux which was identified as 2-oxopyridine thiadiazole derivative 6a (major product, Scheme 2), while acidification of the reaction filtrate with cold dilute HCl furnished an orange precipitate that was detected as the arylidene derivative 6b (minor product). Furthermore, the Knoevenagel condensation of 1,3,4-thiadiazole derivative 3 with aromatic aldehydes namely; 2,4-dichlorobenzaldehde, p-chlorobenzaldehyde, furan-2-carbaldehyde, thiophene-2-carbaldehyde, p-nitro benzaldehyde, or 4-hydroxy-3-methoxy benzaldehyde for three hours in refluxing ethanol containing a catalytic amount of piperidine afforded the corresponding arylidene derivatives 7a–f, respectively (Scheme 2). Moreover, the reaction of compound 3 with ethyl 3-(4-chlorophenyl)-2-cyanoacrylate under the same reaction conditions afforded the arylidene derivative 7b rather than 2-oxopyridin derivative 8.
The proclivity of thiadiazole derivative 3 towards β-diketones was also investigated in this study. Thus, 2-pyridone derivatives 9 and 10 were obtained from the reaction of 3 with acetyl acetone and benzoyl acetone, respectively in ethanolic solution containing catalytic amount of fused sodium acetate (Scheme 3). 1H-NMR spectrum of compound 9 showed signals at 3.96 and 3.99 ppm which were attributed to protons of CH3 group, as well as the absence of a singlet signal for protons of CH2CN group which confirmed the proposed structure 9. Furthermore, the 13C-NMR spectrum revealed the presence of two methyl groups at δ 21.01 and 21.12 ppm (Scheme 3).
![image file: d3ra02716c-s3.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-s3.gif) |
| Scheme 3 Synthesis of some new 2-pyridone derivatives (9 and 10) from the cyanoacetamide 3. | |
At room temperature, the active methylene moiety in the cyanoacetamide derivative 3 readily adds to one carbon donor such as phenyl isothiocyanate in DMF-containing potassium hydroxide forming a non-isolable intermediate potassium thiocarbamate salt (A), which in situ reacted with ethyl chloroacetate, chloroacetyl chloride, diethylmalonate, 1,2-dibromo ethane, methyliodide, or hydrochloric acid giving the corresponding ethyl thioacetate, 1,3-thiazolone, 4,6-dioxo-1,3-thiazinan, 1,3-thiazole, thiadiazolo[3,2-a]pyrimidin, and thioxopropanamide derivatives 11–16, respectively (Scheme 4). The structures of derivatives 11–16 were clarified using elemental analysis and spectral data (c.f. experimental). For instance, the appearance of strong absorption bands in the IR spectrum at 2195 and 1734 cm−1 for C
N and C
Oester groups, respectively was completely consistent with the suggested structure 11 and ruled out the cyclized compound 12.
![image file: d3ra02716c-s4.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-s4.gif) |
| Scheme 4 Reaction of potassium thiocarbamate (A) with some electrophiles. | |
Likewise, addition of 1,3,4-thiadiazole derivative 3 to carbon disulfide in DMF-containing potassium hydroxide at room temperature gave the non-isolable dipotassium dithiocarbazate salt (B), which in situ reacted with methyl iodide affording the ketene S,S-dithioacetal 17 (Scheme 5). The elemental analysis and spectral data were used to determine the structure of compound 17.
![image file: d3ra02716c-s5.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-s5.gif) |
| Scheme 5 Treatment of the ketene S,S-dithioacetal 17 with some bidentate nucleophiles. | |
Further, the reactivity of 17 towards some nitrogen and oxygen nucleophiles was investigated. Thus, compound 17 reacted under reflux with bidentate nucleophiles such as o-phenylenediamine, o-aminophenol, or 2,3-dihydroxy pyridine giving the corresponding benzimidazole derivative 18, benzoxazole derivative 19, and dioxolo[4,5-b]pyridine derivative 20, respectively (Scheme 5). The structures of compounds 18–20 were consistent with the 1H-NMR and 13C-NMR spectra which revealed the absence of two SCH3 groups.
3.2 Biological evaluation
3.2.1 Antiproliferative activity. According to the National Cancer Institute (NCI) criteria, only novel moieties with antiproliferative activity at 10 μM or less against cancer cell lines are considered for further studies.37 Based on this criterion, only derivatives 4, 6b, 7a, 7d, and 19 are to be considered (Table 1). However, derivatives 4 and 7d were only effective against the breast cells and with very low selectivity. Although derivative 7a was effective against all cell lines investigated, it has a low selectivity index (SI = 1.5). In other words, derivatives 4, 7a, and 7d were as toxic to the cancer cells as to the normal fibroblasts, and therefore, these derivatives were excluded from further investigations (Table 1). Derivatives 6b and 19 with IC50 at less than 10 μM against the breast, colon, and prostate cell lines and with high selectivity (SI = ∼5 and 6 folds, respectively), were selected for further studies. It is noteworthy that other than 7a, no other derivative exhibited a significant antiproliferative activity against the liver HepG2 cells. It is also noteworthy that 18 compounds out of 24 were toxic (not selective) to the normal fibroblasts. Doxorubicin had antiproliferative activity against all cell lines investigated with no selectivity (SI = 1.2). The breast cells (MCF-7) were the most responsive to the thiadiazole derivatives. Therefore, these cells were selected for further investigations on compounds 6b and 19.
Table 1 The antiproliferative activity (IC50 in μM) of the new thiadiazole derivatives against human breast (MCF-7), colon (HCT-116), prostate (PC-3), and liver (HepG2) cell lines, and normal fibroblasts (WI-38) and their selectivity index (SI)a
Cpds |
MCF-7 |
HCT-116 |
PC-3 |
HepG2 |
WI-38 |
SIc |
The IC50 was calculated from a dose–response curve. Doxorubicin (Dox) was used as a positive control. The data are expressed as mean ±SEM from three independent experiments. Significant (less than 10 μM) antiproliferative activity as compared to the untreated cells. SI: selectivity index = WI-38 IC50/IC50 against cancer cells. |
DOX |
4.17 ± 0.2b |
5.23 ± 0.3b |
8.87 ± 0.6b |
4.50 ± 0.2b |
6.72 ± 0.5b |
1.2 |
2 |
12.36 ± 3.0 |
15.26 ± 2.8 |
30.01 ± 3.1 |
14.11 ± 1.5 |
17.56 ± 4.1 |
1.0 |
3 |
23.81 ± 1.9 |
25.72 ± 1.9 |
39.23 ± 2.8 |
31.26 ± 5.1 |
37.41 ± 2.5 |
1.2 |
4 |
8.25 ± 3.5b |
15.84 ± 3.2 |
20.97 ± 3.3 |
48.51 ± 2.9 |
29.35 ± 2.2 |
1.3 |
5 |
64.12 ± 3.8 |
47.22 ± 3.5 |
66.53 ± 3.9 |
63.93 ± 8.9 |
91.23 ± 4.6 |
1.5 |
6a |
41.57 ± 2.7 |
29.19 ± 2.3 |
35.76 ± 2.6 |
54.62 ± 6.8 |
18.64 ± 1.4 |
0.5 |
6b |
9.48 ± 0.8b |
8.15 ± 0.7b |
7.41 ± 0.6b |
15.88 ± 1.3 |
50.39 ± 0.9 |
4.9 |
7a |
5.51 ± 0.4b |
3.97 ± 0.2b |
9.10 ± 0.8b |
6.34 ± 0.9b |
9.18 ± 3.6b |
1.5 |
7b |
17.73 ± 0.6 |
16.18 ± 0.4 |
21.86 ± 1.1 |
14.68 ± 2.1 |
42.06 ± 2.7 |
2.4 |
7c |
28.13 ± 3.5 |
52.63 ± 3.7 |
13.30 ± 3.6 |
16.34 ± 1.8 |
22.57 ± 3.0 |
0.8 |
7d |
8.02 ± 1.4b |
34.14 ± 2.6 |
11.12 ± 4.7 |
66.10 ± 3.5 |
12.28 ± 1.2 |
0.4 |
7e |
45.11 ± 4.0 |
51.39 ± 4.1 |
75.22 ± 4.7 |
56.33 ± 7.8 |
23.39 ± 3.6 |
0.4 |
7f |
13.59 ± 1.1 |
10.92 ± 0.9 |
18.35 ± 1.5 |
21.26 ± 3.7 |
14.54 ± 0.3 |
0.9 |
9 |
14.13 ± 1.2 |
12.78 ± 1.1 |
15.38 ± 1.3 |
39.07 ± 2.7 |
50.39 ± 0.9 |
2.5 |
10 |
72.41 ± 4.1 |
68.01 ± 3.9 |
86.47 ± 4.8 |
19.40 ± 1.5 |
>100 |
1.7 |
11 |
69.70 ± 3.9 |
63.12 ± 3.8 |
71.94 ± 4.0 |
52.87 ± 4.6 |
22.65 ± 3.8 |
0.4 |
12 |
84.81 ± 4.4 |
91.27 ± 4.6 |
>100 |
69.54 ± 6.5 |
>100 |
1.2 |
13 |
37.95 ± 3.2 |
46.14 ± 3.7 |
73.56 ± 4.3 |
45.21 ± 6.3 |
23.58 ± 3.2 |
0.5 |
14 |
36.23 ± 2.4 |
40.18 ± 3.1 |
92.28 ± 3.2 |
>100 |
53.75 ± 3.4 |
0.8 |
15 |
12.74 ± 2.1 |
17.03 ± 1.4 |
10.49 ± 1.9 |
16.84 ± 1.7 |
19.38 ± 1.5 |
1.4 |
16 |
19.58 ± 1.6 |
21.62 ± 1.7 |
28.80 ± 2.3 |
14.68 ± 2.3 |
85.91 ± 1.9 |
4.1 |
17 |
15.10 ± 1.3 |
14.67 ± 0.9 |
12.17 ± 0.8 |
12.47 ± 1.0 |
81.20 ± 4.1 |
6.0 |
18 |
84.65 ± 4.6 |
56.85 ± 3.6 |
81.82 ± 4.5 |
47.33 ± 8.2 |
>100 |
1.5 |
19 |
7.70 ± 0.5b |
5.98 ± 0.3b |
6.35 ± 0.5b |
19.40 ± 1.5 |
60.28 ± 3.7 |
6.1 |
20 |
36.78 ± 2.7 |
18.32 ± 1.7 |
31.39 ± 2.2 |
29.64 ± 3.1 |
42.74 ± 2.7 |
1.5 |
3.2.2 Cell cycle and apoptosis analysis. In the cell cycle analysis assay, the treated cells are stained with propidium iodide (DNA binding stain) and analyzed by flow cytometry. Treatment of MCF7 cells with 19 led to G2/M arrest with 23.3% of cells arrested at this stage compared to 4.6% in the cells treated with DMSO (Fig. 2). The arrested cells usually undergo apoptosis. Compound 6b increased the sub-G1 percent of cells from 7.4% in the DMSO-treated cells to 53.6%. The sub-G1 population is characterized by low DNA level, and it is usually comprised of cell fragments, often because of apoptosis or sometimes necrosis. Since the sub-G1 peak appears very close to the G0/G1 peak, we believe it is mainly due to necrosis rather than to apoptosis. To exclude the contribution of any mechanical stress to the cells from excessive pipetting, vortex, or harsh centrifugation that usually results in elevation of the sub-G1 cell population, the experiment was repeated thrice with much care and restricted gating strategy.
![image file: d3ra02716c-f2.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-f2.gif) |
| Fig. 2 Cell cycle analysis of MCF7 after treatment with derivatives 6b and 19. Data are expressed as means ±SEM (n = 3). The top panel represents one sample, and the bottom figure represents the average of 3 independent experiments expressed as percentage of cells in every stage. | |
The arrest of cells at the G2/M indicates a severe DNA damage that is beyond repair.38 The crucial event in cell-cycle progression through the G2/M checkpoint is the upregulation of expression of Chk2 protein and increase in the phosphorylation of Chk2 and CDC25C, leading to inhibition of the formation CDK1/cyclin B complex and cell cycle arrest at the G2/M phase.39,40 Many proteins such as p53, p21, and p38/MAPK could contribute to the arrest at the G2/M phase.41 p53 induces the transcription of p21 which inhibits CDK resulting in the arrest of cells at the G2/M.42,43 In the current study, we have not investigated these different pathways.
We have also measured apoptosis by annexin V-PI assay. The level of apoptotic cells either in the early stage (lower-right quadrant, LR) or late apoptotic stage (upper-right quadrant, UR), in addition to the necrotic cells in the upper left (UL) quadrant were all quantified by flow cytometry (Fig. 3). It is evident that compound 6b did not induce apoptosis and increased the necrotic cells by 12.5% compared to 0.1% when the cells were treated with DMSO. This confirms the data we have obtained from the cell cycle analysis. As expected, compound 19 significantly increased the early apoptosis to 15% and increased the necrotic cells to 15% (Fig. 3). Compound 19 evidently arrested the cells at the G2/M forcing them to apoptosis possibly through induction of p53 and different caspases.44–46 Derivatives 6b and 19 induced necrosis in addition to the apoptosis caused by derivative 19. Although the importance of necrosis in the cancer therapy is not as fully understood as apoptosis, recent studies suggest that necrosis or necroptosis have potential applications as anticancer target.47,48
![image file: d3ra02716c-f3.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-f3.gif) |
| Fig. 3 Detection of apoptosis by derivatives 6b and 19 in MCF7 cells by flow cytometry. | |
3.3. In silico studies
3.3.1 Molecular docking study. First, two validation procedures were completed to verify the MOE program's reliability in producing accurate docking results. This was proven by redocking the co-crystallized inhibitor of the CDK-1.49 The successful execution of the docking protocol was guaranteed by the low values of RMSD = 1.043 Å that were obtained between the native and redocked poses of the co-crystallized inhibitor.50It was shown that FB8, a native co-crystallized inhibitor of the CDK-1, forms four H-bonds with the amino acids Glu81, Leu83, Leu83 and Lys89, one ionic bond with Asp146, and one pi-bond with Phe80.49 More thorough research and comparisons with the docked FB8 of the CDK-1 binding pocket was conducted on the two most promising biologically active newly synthesized thiadiazol derivatives (6b and 19). After looking at the binding modes of the aforementioned compounds (Fig. 4), we concluded that:
![image file: d3ra02716c-f4.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-f4.gif) |
| Fig. 4 The interactions of the most promising derivatives (6b and 19) at CDK-1 binding pocket, alongside the docked co-crystallized inhibitor (FB8), are depicted in 2D and 3D interactions. H-bonds (dashed blue lines), ionic bond (red dashed lines) and H–pi bonds (green dashed lines). | |
(a) Compound 6b formed a H-bond donor with the Asp146 amino acids at 2.97 Å and a H-bond acceptor with the Leu83 amino acid at 3.17 Å when positioned inside the largest binding pocket of the CDK-1 (S = −7.220 kcal mol−1 and RMSD = 1.713). It is not a good inhibitor of the enzyme.
(b) Compound 19 formed two H-bonds donor with Leu83 and Asp86 amino acids at 3.53 and 2.93 Å, respectively. Furthermore, it formed two H-bonds acceptor with Lys89 and Leu83 amino acid at 3.03 and 3.18 Å, respectively, as well as two pi–H bonds with Val18 and Lys89 amino acids at 3.78 and 3.66 Å, respectively inside the binding site of the CDK-1 (S = −6.671 kcal mol−1 and RMSD = 1.067). Therefore, compound 19 is a good CDK1 inhibitor candidate.
(c) Finally, it was shown that the docked co-crystallized inhibitor of the CDK-1 (FB8, S = −6.787 kcal mol−1 and RMSD = 1.124) formed two H-bonds donor with Glu81 and Leu83 amino acid at 3.39 and 2.99 Å, respectively. Furthermore, it formed two H-bonds acceptor with Leu83 and Lys89 amino acid at 3.42 and 3.13 Å, respectively. Also, formed one pi–H bond with Phe80 amino acids at 4.42 Å. In addition to one ionic bond with Asp146 amino acid at 4.42 Å.
3.3.2 Pharmacokinetics profiling study. In the current study, FB8 was used as a reference compound to assess the pharmacokinetics and physicochemical properties of all the designed compounds in silico.51,52 According to Lipinski, a molecule is predicted to be absorbed more effectively if it complies with at least three of the following four principles: (i) molecular weight <500; (ii) H-bond donors [HBD] (OH, NH, and SH) ≤5; (iii) H-bond acceptors [HBA] (N, O, and S atoms) ≤10; (iv) log
P < 5. More than one of these requirements must be met for a compound to have a high level of bioavailability. Additionally, it was found that the number of rotatable bonds and the reduction in molecular flexibility were important indicators of excellent oral bioavailability.53 For substances with ten or fewer rotatable bonds and a molecular polar surface area of 140 Å or less, oral bioavailability is likely to be high.54Except for compound 11, which violates more than one of the Lipinski's rule of five, all tested, and reference compound (FB8) listed in Table 2 displayed drug-like molecular (DLM) nature, according to the study. Only one of Lipinski's rule of five was violated and only by compound 11. All other investigated molecules had log
P, molecular weight, number of H-bond donors, and number of H-bond acceptors less than 5, 500, 5, and 10, respectively. Except for compound 11, which showed 13 rotatable bonds, all the examined molecules' topology polar surface areas (TPSA) and numbers of ratable bonds fall within the acceptable ranges of less than 10 and 140 Å, respectively.
Table 2 Physicochemical characteristics of the new thiadiazole derivatives and the reference compound
Comp |
Lipinski's rule of five |
Verber's rule |
log P |
Mol. wt |
HBD |
HBA |
Violation of Lipinski's rule |
Number of rotatable bonds |
TPSA |
2 |
1.13 |
220.25 |
2 |
3 |
0 |
3 |
109.14 |
3 |
0.95 |
287.30 |
2 |
5 |
0 |
6 |
136.01 |
4 |
2.66 |
391.40 |
3 |
6 |
0 |
6 |
149.21 |
5 |
2.57 |
392.39 |
2 |
6 |
0 |
6 |
142.43 |
6a |
2.42 |
469.48 |
2 |
7 |
0 |
6 |
187.95 |
6b |
2.58 |
405.43 |
2 |
6 |
0 |
8 |
145.24 |
7a |
3.59 |
444.29 |
2 |
5 |
0 |
7 |
136.01 |
7b |
3.07 |
409.85 |
2 |
5 |
0 |
7 |
136.01 |
7c |
1.86 |
365.37 |
2 |
6 |
0 |
7 |
149.15 |
7d |
2.53 |
381.43 |
2 |
5 |
0 |
7 |
164.25 |
7e |
1.91 |
420.40 |
2 |
7 |
0 |
8 |
181.83 |
7f |
2.25 |
421.43 |
3 |
7 |
0 |
8 |
165.47 |
9 |
2.39 |
351.38 |
1 |
5 |
0 |
4 |
128.91 |
10 |
3.30 |
413.45 |
1 |
5 |
0 |
5 |
128.91 |
11 |
3.00 |
508.57 |
3 |
7 |
2 |
13 |
199.64 |
12 |
2.32 |
462.50 |
2 |
6 |
0 |
7 |
181.62 |
13 |
1.88 |
490.51 |
2 |
7 |
0 |
7 |
198.69 |
14 |
2.62 |
448.52 |
2 |
5 |
0 |
7 |
164.55 |
15 |
2.57 |
388.40 |
2 |
5 |
0 |
5 |
140.42 |
16 |
2.45 |
422.48 |
3 |
5 |
0 |
9 |
180.13 |
17 |
2.16 |
391.49 |
2 |
5 |
0 |
8 |
186.61 |
18 |
1.78 |
403.42 |
4 |
5 |
0 |
6 |
167.59 |
19 |
2.11 |
404.40 |
3 |
6 |
0 |
6 |
164.94 |
20 |
1.60 |
406.37 |
2 |
8 |
0 |
6 |
167.36 |
FB8 |
2.51 |
371.46 |
1 |
5 |
0 |
5 |
98.15 |
3.3.3 ADMET analysis. All the compounds examined were subjected to ADMET analyses using Discovery Studio 2.5, with the reference compound FB8. Many descriptors were used in ADMET evaluations, including hepatotoxicity, intestinal absorption, aqueous solubility, plasma protein binding, and molecular blood–brain barrier (BBB) penetration,55 Table 3.
Table 3 Predicted ADMET descriptions for the thiadiazoles and FB8
Comp |
BBB levela |
Absorption levelb |
Hepatotoxicity probabilityc |
PPBd |
BBB level, blood–brain barrier level, 0 = very high, 1 = high, 2 = medium, 3 = low, 4 = very low. Absorption level, 0 = good, 1 = moderate, 2 = poor, 3 = very poor. Hepatotoxicity probability, value > 0.5 means toxic, value < 0.5 means non-toxic. PPB, plasma protein binding, 0 means less than 90%, 1 means more than 90%, 2 means more than 95%. |
2 |
0 |
0 |
0.857 |
0 |
3 |
1 |
0 |
0.901 |
0 |
4 |
0 |
0 |
0.834 |
2 |
5 |
4 |
2 |
0.518 |
2 |
6a |
1 |
0 |
0.909 |
2 |
6b |
1 |
0 |
0.878 |
2 |
7a |
4 |
1 |
0.89 |
2 |
7b |
4 |
1 |
0.530 |
2 |
7c |
4 |
1 |
0.887 |
2 |
7d |
4 |
2 |
0.87 |
2 |
7e |
4 |
2 |
0.516 |
2 |
7f |
4 |
2 |
0.894 |
2 |
9 |
0 |
0 |
0.86 |
2 |
10 |
1 |
0 |
0.974 |
1 |
11 |
0 |
0 |
0.907 |
2 |
12 |
2 |
0 |
0.859 |
2 |
13 |
4 |
2 |
0.905 |
2 |
14 |
4 |
2 |
0.955 |
2 |
15 |
1 |
0 |
0.905 |
2 |
16 |
1 |
0 |
0.865 |
2 |
17 |
1 |
0 |
0.794 |
2 |
18 |
0 |
0 |
0.92 |
2 |
19 |
1 |
0 |
0.973 |
1 |
20 |
0 |
0 |
0.912 |
2 |
FB8 |
0 |
2 |
0.517 |
1 |
The results showed that BBB penetration levels varied from none (derivatives 2, 4, 9, 11, 18, and 20, in addition to FB8) to very high (derivatives 5, 7a–f, 13, and 14). Derivatives 3, 6a, 6b, 10, 12, 15–17, and 19 showed low penetration ability to the BBB. Most important that derivatives 6b and 19 are safe to the CNS.
Clinical trials for a number of pharmaceutical candidates have been documented as being unsuccessful because of absorption issues.56 Intestinal absorption is the proportion of a drug that is taken up by the intestinal mucosa. A drug is well-absorbed if at least 90% of it is absorbed into the bloodstream.57 All the tested compounds, except for 5, 7a–f, 13 and 14, which showed moderate to poor levels of absorption, have good absorption properties, according to the findings of these studies. All the novel compounds as well as the reference compound could have potential hepatotoxic effects according to predictions. All tested members and reference compound can bind plasma protein greater than 90% (highly bound), except for compounds 2 and 3, which showed plasma protein binding less than 90%.
3.4 Structure activity relationship (SAR) study
The SAR of the newly synthesized derivatives of the two series of thiadiazole and benzoxazole-based yields very promising results.
(i) Concerning the antiproliferative activity of thiadiazole-based derivatives, compound 6b was found to be superior to compound 7a and then compound 7d on the four cell lines studied. This indicates that the 4-CH3 substituent on the side phenyl moiety is superior to the 2,4-diCl substituent, which is also superior to the thiophene moiety.
(ii) In contrast, we can conclude about the benzoxazole-based candidate compound 19 with benzo[d]oxazole ring together with the thiadiazole moiety achieved the best antiproliferative actions. The cyanoacetamido moiety in position-2 of the benzoxazole ring and benzamide side chain, demonstrated strong antiproliferative effects on all four cancer cell lines.
(iii) Derivative 19 shares some of the common characteristics of the known CDK1 inhibitors (Fig. 5). These include a hydrophobic head to occupy the hydrophobic region I, an H-bond donor in the spacer moiety, a flat heteroaromatic ring to occupy the ATP-binding pocket, and a hydrophobic tail to occupy the hydrophobic region I. In addition, derivative 19 has various H-bond donor and/or acceptor moieties such as cyanoacetamide. The presence of a linker (thiourea or cyanoacetamide) or rigidified to heteroaromatic ring facilitates the occupation to the hydrophobic region of the enzyme. A substituted phenyl ring and heteroaromatic ring with various electron-donating or withdrawing groups added to the aforementioned core probably improved the inhibiting potential of derivative 19.
![image file: d3ra02716c-f5.tif](/image/article/2023/RA/d3ra02716c/d3ra02716c-f5.gif) |
| Fig. 5 Derivative 19 as a potential inhibitor of CDK1. | |
4. Conclusion
In this study, a group of 24 annulated 1,3,4-thiadiazole compounds were synthesized and investigated as anticancer agents. Only five derivatives had a significant antiproliferative activity against a panel of four cancer cell lines. However, three of these were not selective and caused toxicity to the normal cells. Two derivatives 6b and 19 were effective and selective. Compound 19 arrested the MCF-7 cells at the G2/M phase probably through inhibition of CDK1 and elicited apoptosis in these cells confirmed by the annexin V-PI assay. Compound 6b acted through a different pathway and significantly increased the sub-G1 percent of cells probably through induction of necrosis. Molecular docking showed that compound 19 is a potential CDK1 inhibitor candidate. Derivatives 6b and 19 did not violate Lipinski's rule of five and therefore, they are considered hits for further drug discovery research. In silico studies showed that these derivatives also have a low blood–brain barrier penetration capability and high intestinal absorption. Taken together, derivatives 6b and 19 could serve as potential anticancer agents and merit further investigations.
Author contributions
Data curation: PSF and WME. Formal analysis: PSF and WME. Investigation: MHH, PSF, and WME. Writing – original draft: MHH, PSF, and WME. Conceptualization: MHH, MMH, WME. Supervision: MMH. Resources: AAE, AIH, WME. Software: PSF. Methodology: MHH, PSF, and WME. Validation: MHH, WME. Writing – review & editing: PSF, and WME. All authors read and approved the final version of the manuscript.
Conflicts of interest
Authors declare that they have no conflict of interest.
References
- A. Kumar, A. K. Singh, H. Singh, V. Vijayan, D. Kumar and J. Naik, et al., Pharmaceuticals, 2023, 16(2), 1–68 Search PubMed
. - S. Pearce, Drug Discvery, 2017, 67, 66–70 Search PubMed
. - J. Bostrom, A. Hogner, A. Llinas, E. Wellner and A. T. Plowright, J. Med. Chem., 2012, 55, 1817–1830 CrossRef PubMed
. - C. D. Monte, S. Carradori, D. Secci, M. D'Ascenzio, P. Guglielmi, A. Mollica, S. Morrone, S. Scarpa, A. M. Aglianò, S. Giantulli and I. Silvestri, Eur. J. Med. Chem., 2015, 105, 245–262 CrossRef PubMed
. - R. W. Sidwell, R. K. Robins and I. W. Hillyard, Pharmacol. Ther., 1979, 6, 123–146 CrossRef CAS PubMed
. - M. D. Mullican, M. W. Wilson, D. T. Conner, C. R. Kostlan, D. J. Schrier and R. D. Dyer, J. Med. Chem., 1993, 36, 1090–1099 CrossRef CAS PubMed
. - P. Datar and T. Deokule, Med. Chem., 2014, 4, 390–399 Search PubMed
. - F. Clerici, D. Pocar, M. Guido, A. Loche, V. Perlini and M. Brufani, J. Med. Chem., 2001, 44, 931–936 CrossRef CAS PubMed
. - H. Foks, D. P. Ksepko and K. Gobis, J. Heterocycl. Chem., 2014, 51, 507–512 CrossRef CAS
. - G. Serban, Molecules, 2020, 25, 942 CrossRef CAS PubMed
. - N. Shivakumara and P. M. Krishna, J. Mol. Struct., 2020, 1199, 126999 CrossRef
. - P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, J. Natl. Cancer Inst., 1990, 82, 1107–1112 CrossRef CAS PubMed
. - A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo and M. Boyd, J. Natl. Cancer Inst., 1991, 83, 757–766 CrossRef CAS PubMed
. - W. M. El-Sayed, W. M. Hussin, A. A. Mahmoud and M. A. AlFredan, Biomed. Res. Int., 2013, 2013, 1–11 CrossRef PubMed
. - M. A. Ismail, G. A. Abdelwahab, W. S. Hamama, E. Abdel-Latif, F. E. Fardous and W. M. El-Sayed, Arch. Pharm., 2022, e2100385 CrossRef PubMed
. - A. A. Al-Karmalawy, M. A. Dahab, A. M. Metwaly, S. S. Elhady, E. B. Elkaeed, I. H. Eissa and K. M. Darwish, Front. Chem., 2021, 9, 24–44 Search PubMed
. - H. Y. Aati, A. Ismail, M. E. Rateb, A. M. AboulMagd, H. M. Hassan and M. H. Hetta, Plants, 2022, 11, 2521 CrossRef CAS PubMed
. - M. I. A. Hamed, K. M. Darwish, R. Soltane, A. Chrouda, A. Mostafa, N. M. Abo Shama, S. S. Elhady, H. S. Abulkhair, A. E. Khodir, A. A. Elmaaty and A. A. Al-karmalawy, RSC Adv., 2021, 11, 35536–35558 RSC
. - K. El-Adl, M.-K. Ibrahim, M. S. Alesawy and I. H. Eissa, Bioorg. Med. Chem., 2021, 30, 115958 CrossRef CAS PubMed
. - M. S. Alesawy, E. B. Elkaeed, A. A. Alsfouk, A. M. Metwaly and I. Eissa, Molecules, 2021, 26, 6593 CrossRef CAS PubMed
. - M. H. Hekal, F. S. M. Abu El-Azm and S. R. Atta-Allah, Synth. Commun., 2019, 49, 2630–2641 CrossRef CAS
. - M. H. Hekal, F. S. M. Abu El-Azm and H. A. Sallam, J. Heterocycl. Chem., 2019, 56, 795–803 CrossRef CAS
. - M. A. Yousef, A. M. Ali, W. M. El-Sayed, W. Saber, H. H. Farag and T. Aboul-Fadl, Bioorg. Chem., 2020, 105, 104366 CrossRef CAS PubMed
. - M. H. Hekal, A. M. El-Naggar, F. S. M. Abu El-Azm and W. M. El-Sayed, RSC Adv., 2020, 10, 3675–3688 RSC
. - M. S. Salem, R. A. Hussein and W. M. El-Sayed, Med. Chem., 2019, 19, 620–626 CAS
. - A. M. El-Naggar, A. K. Khalil, H. M. Zeidan and W. M. El-Sayed, Med. Chem., 2017, 17, 1644–1651 CAS
. - W. A. Hussin, M. A. Ismail, A. M. Alzahrani and W. M. El-Sayed, Drug Des., Dev. Ther., 2014, 8, 963–972 CAS
. - M. R. Franklin, P. J. Moos, W. M. El-Sayed, T. Aboul-Fadl and J. C. Roberts, Chem.–Biol. Interact., 2007, 168, 211–220 CrossRef CAS PubMed
. - M. H. Hekal, S. S. Samir, Y. M. Ali and W. M. El-Sayed, Polycycl. Aromat. Compd., 2022, 42, 7644–7660 CrossRef CAS
. - W. S. Qayed, M. A. Hassan, W. M. El-Sayed, J. R. A. Silva and T. Aboul-Fadl, Bioorg. Chem., 2022, 126, 105884 CrossRef CAS PubMed
. - W. M. El-Sayed, T. Aboul-Fadl, J. C. Roberts, J. G. Lamb and M. R. Franklin, Toxicol. In Vitro, 2007, 21, 157–164 CrossRef CAS PubMed
. - S. R. Atta-Allah, A. M. AboulMagd and P. S. Farag, Bioorg. Chem., 2021, 112, 104923 CrossRef CAS PubMed
. - P. S. Farag, M. M. Hemdan and A. A. El-Sayed, J. Heterocycl. Chem., 2020, 57, 3428–3441 CAS
. - P. S. Farag, A. M. AboulMagd, M. M. Hemdan and A. I. Hassaballah, Bioorg. Chem., 2023, 130, 106231 CrossRef CAS PubMed
. - P. S. Farag, M. M. Hemdan and A. I Hassaballah, RSC Adv., 2022, 12, 10204–10208 RSC
. - M. H. Hekal, P. S. Farag, M. M. Hemdan and W. M. El-Sayed, Bioorg. Chem., 2021, 115, 105176 CrossRef CAS PubMed
. - S. L. Holbeck, J. M. Collins and J. H. Doroshow, Mol. Cancer Ther., 2010, 9(5), 1451–1460 CrossRef CAS PubMed
. - A. Lezaja and M. Altmeyer, Cell Cycle, 2018, 17, 24–32 CrossRef CAS PubMed
. - T. C. Tsou, F. Y. Tsai, S. C. Yeh and L. W. Chang, Arch. Toxicol., 2006, 80, 804–810 CrossRef CAS PubMed
. - M. C. Chang, Y. J. Chen, E. J. Liou, W. Y. Tseng, C. P. Chan, H. J. Lin, W.-C. Liao, Y.-C. Chang, P.-Y. Jeng and J.-H. Jeng, Oncotarget, 2016, 7, 74473–74483 CrossRef PubMed
. - M. Zhang, J. Qu, Z. Gao, Q. Qi, H. Yin, L. Zhu, Y. Wu, W. Liu, J. Yang and X. Huang, Front. Pharmacol., 2021, 11, 601468 CrossRef PubMed
. - S. A. El-Metwally, A. K. Khalil and W. M. El-Sayed, Bioorg. Chem., 2020, 94, 103492 CrossRef CAS PubMed
. - A. Arora and E. M. Scholar, J. Pharmacol. Exp. Ther., 2005, 315, 971–979 CrossRef CAS PubMed
. - T. Ozaki and A. Nakagawara, J. Biomed. Biotechnol., 2011, 3, 994–1013 CAS
. - M. Olsson and B. Zhivotovsky, Cell Death Differ., 2011, 18, 1441–1449 CrossRef CAS PubMed
. - C. M. Pfeffer and A. T. K. Singh, Int. J. Mol. Sci., 2018, 19, 1–10 Search PubMed
. - J. Yan, P. Wan, S. Choksi and Z. G. Liu, Trends Cancer, 2022, 8, 21–27 CrossRef CAS PubMed
. - Z. G. Liu and D. Jiao, Cell Stress, 2019, 4, 1–8 CrossRef PubMed
. - D. J. Wood, S. Korolchuk, N. J. Tatum, L. Wang, J. A. Endicott, M. E. M. Noble and M. P. Martin, Cell Chem. Biol., 2019, 26, 121–130 CrossRef CAS PubMed
. - N. Malhotra, R. Gupta and P. KumarR, Neurochem. Int., 2021, 148, 105115 CrossRef CAS PubMed
. - L. L. G. Ferreira and A. D. Andricopulo, Drug Discov. Today, 2019, 24, 1157–1165 CrossRef CAS PubMed
. - T. Khan, M. Ali, A. Khan, P. Nisar, S. A. Jan and S. A. Z. K. Shinwari, Biomolecules, 2020, 10, 47 CrossRef CAS PubMed
. - F. Wu, Y. Zhou, L. Li, X. Shen, G. Chen, X. Wang, X. Liang, M. Tan and Z. Huang, Front. Chem., 2020, 8, 726 CrossRef CAS PubMed
. - D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, J. Med. Chem., 2002, 45, 2615–2623 CrossRef CAS PubMed
. - H. Patel, K. Dhangar, Y. Sonawane, S. Surana, R. Karpoormath, N. Thapliyal, M. Shaikh, M. Noolvi and R. Jagtap, Arabian J. Chem., 2015, 11, 221–232 CrossRef
. - A. K. Jain, S. Sharma, A. Vaidya, V. Ravichandran and R. K. Agrawal, Chem. Biol. Drug Des., 2013, 81, 557–576 CrossRef CAS PubMed
. - A. Tahghighi and F. Babalouei, Iran. J. Basic Med. Sci., 2017, 20, 613–622 Search PubMed
.
|
This journal is © The Royal Society of Chemistry 2023 |